MainStreet Investment Advisors LLC trimmed its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 4.5% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 64,072 shares of the company's stock after selling 3,008 shares during the period. AbbVie accounts for about 2.0% of MainStreet Investment Advisors LLC's holdings, making the stock its 11th biggest holding. MainStreet Investment Advisors LLC's holdings in AbbVie were worth $13,424,000 as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of ABBV. tru Independence LLC increased its holdings in shares of AbbVie by 4.4% in the first quarter. tru Independence LLC now owns 19,107 shares of the company's stock valued at $4,003,000 after purchasing an additional 799 shares during the last quarter. Heritage Wealth Management Inc. CA purchased a new stake in AbbVie in the 1st quarter valued at $258,000. Rogco LP increased its stake in shares of AbbVie by 1.1% in the 1st quarter. Rogco LP now owns 7,836 shares of the company's stock worth $1,642,000 after acquiring an additional 89 shares during the last quarter. Ascent Capital Management LLC purchased a new position in shares of AbbVie during the 1st quarter worth $237,000. Finally, Quotient Wealth Partners LLC boosted its position in shares of AbbVie by 9.8% during the 1st quarter. Quotient Wealth Partners LLC now owns 7,884 shares of the company's stock valued at $1,652,000 after acquiring an additional 702 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
AbbVie Stock Up 2.3%
NYSE ABBV traded up $4.34 on Thursday, hitting $194.96. 6,044,962 shares of the stock were exchanged, compared to its average volume of 6,297,739. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $218.66. The company has a 50-day moving average price of $187.10 and a 200-day moving average price of $188.78. The company has a quick ratio of 0.64, a current ratio of 0.76 and a debt-to-equity ratio of 44.14. The company has a market cap of $344.38 billion, a PE ratio of 18.56, a PEG ratio of 1.29 and a beta of 0.48.
AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, topping analysts' consensus estimates of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The firm had revenue of $13.34 billion during the quarter, compared to the consensus estimate of $12.91 billion. During the same quarter in the previous year, the firm posted $2.31 earnings per share. The company's revenue was up 8.4% compared to the same quarter last year. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.
AbbVie Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be given a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a yield of 3.36%. AbbVie's dividend payout ratio (DPR) is presently 279.15%.
Analyst Ratings Changes
ABBV has been the subject of several recent analyst reports. Morgan Stanley raised their price objective on shares of AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a research report on Monday, April 28th. Guggenheim increased their price objective on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Wall Street Zen lowered AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. BNP Paribas upgraded AbbVie to a "hold" rating in a report on Thursday, May 8th. Finally, Erste Group Bank upgraded shares of AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Eight research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $211.29.
Get Our Latest Report on AbbVie
About AbbVie
(
Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Recommended Stories

Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.